$ARDT

Ardent Health, Inc. (ARDT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ardt-q226x8xkxex991.htm EX-99.1 ARDT - Q2 26 - 8-K - EX99.1 1 Exhibit 99.1 Ardent Health Reports Second Quarter 2026 Results Brentwood, Tenn. ( August 4, 2026 ) – Ardent Health, Inc. (NYSE: ARDT) ("Ardent Health" or the "Company"), a leading provider of healthcare in gr

Ardent Health, Inc. (ARDT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex101-separationrelease.htm EX-10.1 EX10.1 - Separation, Release 4930-6561-1447v.1 EXHIBIT 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (this “Agreement”) dated as of June 26, 2026, is entered into by and between AHS Manage

DeMichiei Robert purchased 11,260 shares of Ardent Health, Inc. (ARDT) at $8.73 on 2026-06-05.

LUMSDAINE ALFRED (Chief Financial Officer) purchased 10,000 shares of Ardent Health, Inc. (ARDT) at $8.81 on 2026-06-05.

Ardent Health, Inc. reported its first-quarter 2026 results, showing a 7.0% increase in total revenue year-over-year to $1.60 billion and a 26.3% rise in Adjusted EBITDA to $124 million. Despite a slight decrease in admissions due to severe weather and a lighter respiratory season, the company reaffirmed its full-year 2026 financial guidance. The strong performance was attributed to disciplined execution, effective cost management, and the positive impact of its IMPACT program.

Faruqi & Faruqi, LLP is reminding investors of Ardent Health (ARDT) that the deadline to seek lead plaintiff status in a federal securities class action lawsuit is March 9, 2026. The lawsuit alleges that Ardent Health and its executives made misleading statements and failed to disclose information regarding the company's accounts receivable. This follows a significant drop in Ardent's stock price after the company announced a $43 million reduction in revenue due to accounting changes and a $54 million increase in professional liability reserves in Q3 2025.

The Schall Law Firm has announced a class action lawsuit against Ardent Health, Inc. (NYSE: ARDT) for alleged securities fraud, encouraging investors who purchased securities between July 18, 2024, and November 12, 2025, to contact the firm. The lawsuit claims Ardent made misleading statements regarding its accounting practices for accounts receivable and failed to maintain adequate professional malpractice liability insurance. Investors have until March 9, 2026, to participate as lead plaintiffs.

Faruqi & Faruqi LLP has initiated an investigation into potential claims against Ardent Health, Inc. for investors who purchased securities between July 18, 2024, and November 12, 2025. Investors are urged to discuss their claims before the March 9, 2026 deadline to seek the role of lead plaintiff in a federal securities class action. The law firm is highlighting concerns for investor rights and potential legal risks that could impact Ardent Health's financial health and stock performance.

Ardent Health is facing a class-action lawsuit following a reported $43 million revenue drop due to accounting changes related to accounts receivable collectability and a significant increase in professional liability reserves. The financial disclosures led to a notable decline in Ardent's stock price, prompting The Portnoy Law Firm to advise investors of their legal rights. Analysts have since lowered price targets for ARDT, with Mizuho and JPMorgan downgrading their outlooks.

Hagens Berman has filed a securities class action lawsuit against Ardent Health, Inc. (NYSE: ARDT) and its executives, alleging that the company misled investors about its revenue recognition systems and professional liability reserves. The lawsuit claims Ardent assured investors of detailed collection reviews but instead used a 180-day "cliff" to fully reserve accounts, leading to a significant revenue slash and increase in professional liability reserves in Q3 2025. Investors who purchased ARDT securities between July 18, 2024, and November 12, 2025, and suffered losses are urged to contact Hagens Berman.